Welcome to our dedicated page for Illumina news (Ticker: ILMN), a resource for investors and traders seeking the latest updates and insights on Illumina stock.
Illumina Inc (NASDAQ: ILMN) is described by the company as a global leader in DNA sequencing and array-based technologies, serving research, clinical, and applied markets across genomics, multiomics, and proteomics. This news page aggregates recent press releases and announcements so readers can follow how Illumina’s technologies, collaborations, and financial disclosures evolve over time.
Company news highlights include product and platform launches, such as Illumina Connected Multiomics, a cloud-based software platform for analyzing and visualizing multiomic data, and Illumina Protein Prep, which the company states delivers broad coverage of the blood proteome and supports large-scale genomics studies. Illumina has also announced the Illumina Billion Cell Atlas, a large genome-wide genetic perturbation dataset developed through its BioInsight business to support AI-driven drug discovery in collaboration with pharmaceutical partners.
Investors can use this news feed to track Illumina’s preliminary financial results, earnings announcements, and capital markets activities, as reflected in press releases tied to quarterly and annual results and conference presentations. The page also captures updates on strategic agreements and acquisitions, including Illumina’s planned acquisition of Standard BioTools’ aptamer-based and functional proteomics business, as described in SEC filings and related communications.
In addition, Illumina’s news often covers leadership appointments, regulatory and market developments, and collaborations with genomics and population health partners such as MyOme. By reviewing these updates in one place, readers can better understand how Illumina positions its sequencing, multiomic, and proteomic offerings and how its corporate strategy and partnerships may influence its role in genomics and precision medicine. Bookmark this page to review new company-issued information as it becomes available.
Illumina (Nasdaq: ILMN) reported Q1 FY2026 revenue of $1.09B (+4.8% YoY) with GAAP operating margin of 19.2%, non-GAAP operating margin of 21.9%, GAAP diluted EPS of $0.87 and non-GAAP diluted EPS of $1.15.
Free cash flow was $251M. On April 28, the board authorized an additional $1.5B share repurchase and raised full‑year revenue and non‑GAAP EPS guidance.
Illumina (NASDAQ: ILMN) on April 16, 2026 launched DRAGEN v4.5, expanding germline, oncology, and multiomic analysis with support for TruPath Genome and the 5-base assay.
Key gains: ~20% reduction in germline small-variant errors versus v4.4, expanded pangenome including Middle Eastern genomes, structural-variant calling for 5-base, ML-driven somatic calling, >90% FFPE SNV false-positive reduction, and oncovirus detection (100% expected detections plus 18 additional).
Illumina (NASDAQ: ILMN) and the Center for Data-Driven Discovery in Biomedicine (D3b) announced a data partnership on April 14, 2026 to analyze 100,000 whole genomes from pediatric patients. The cloud-based platform uses DRAGEN v4.4 and Illumina Connected Analytics to enable cross-cohort, real-time genomic discovery for pediatric cancer and rare disease.
The unified dataset will be available via the Kids First Data Resource Center and support ARPA-H's Pediatric Care eXpansion to link data across >200 pediatric institutions, aiming to accelerate research translation and shorten clinical care timelines.
Illumina (NASDAQ:ILMN) will release first quarter 2026 financial results after market close on Thursday, April 30, 2026. A conference call and live webcast with CEO Jacob Thaysen, PhD, and CFO Ankur Dhingra will follow at 1:30 pm PT / 4:30 pm ET. A replay will be posted on the company's investor website and remain available for at least 30 days.
Illumina (NASDAQ: ILMN) announced Board changes on April 2, 2026: Frances Arnold, Robert S. Epstein, and Gary S. Guthart will retire from the Board in connection with the company's upcoming annual meeting, and the Board has nominated David P. King for election as a director.
Chair Scott Gottlieb thanked the retiring directors for their service and said David King brings operating experience, public company board leadership, and regulatory insight across healthcare and life sciences to support Illumina's next phase of growth and genomics integration into medicine.
Labcorp (NYSE: LH) and Illumina on March 18, 2026 expanded a collaboration to broaden precision oncology testing access via distributed IVD kits, new CGP and WGS test development, and evidence generation to support payer coverage.
Plans include exploring co-commercialization of FDA-authorized PGDx elio plasma focus Dx and FDA-approved TruSight Oncology Comprehensive, and continuing joint studies (one evaluated >7,600 NSCLC samples, detecting actionable variants in >72%).
Illumina (NASDAQ: ILMN) on March 16, 2026 announced a strategic consortium with Veritas Genetics Powered By Fuze Health to integrate whole-genome sequencing into preventive care via health plans. The collaboration combines Illumina sequencing and informatics with Veritas patient-ready reporting to enable earlier risk detection, integrated care pathways, and a consented clinical-genomics dataset.
The program targets hereditary cancer, cardiometabolic risk, and medication response, and includes sample collection, confirmatory testing, counseling, and industry data partnerships.
Illumina (NASDAQ: ILMN) and NashBio announced expansion of the Alliance for Genomic Discovery on March 5, 2026: the core dataset grows to 312,000 whole genomes with longitudinal clinical data and a new multiomic initiative will add 50,000 whole genomes paired with proteomic data using Illumina Protein Prep.
Regeneron Genetics Center joins as the tenth member, and GSK is among the first participants in the proteomics expansion. Illumina's recent acquisition of SomaLogic proteomics technologies is cited as enabling the multiomic effort.
Illumina (NASDAQ: ILMN) announced on February 27, 2026 that Illumina Laboratory Services will provide clinical whole-genome sequencing and interpretation services to the Diagnostic Lab at the Florida Institute for Pediatric Rare Diseases (IPRD) at Florida State University College of Medicine. The collaboration aims to accelerate rare-disease diagnostics and shorten the diagnostic odyssey for patients.
The partnership builds on existing ties with FSU, used Illumina implementation support for workflow enablement, and coincides with Rare Disease Day events and a livestreamed talk by Illumina's chief medical officer.
Illumina (NASDAQ: ILMN) highlighted customer breakthroughs in oncology on Feb. 25, 2026, using spatial transcriptomics, 5-base sequencing, proteomics, and Illumina Connected Multiomics. Key claims include whole-transcriptome spatial datasets at 1 µm resolution, >2,000 unique transcripts per cell, and integrated methylation-aware cfDNA insights for harder-to-detect tumors.